These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30875150)

  • 1. Adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Maghzi H; Hogg EJ; Tan E; Pagano G; Tagliati M
    Mov Disord; 2019 Mar; 34(3):442. PubMed ID: 30875150
    [No Abstract]   [Full Text] [Related]  

  • 2. Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences.
    Montastruc JL; Senard JM; Rascol O; Rascol A
    Adv Neurol; 1996; 69():377-81. PubMed ID: 8615154
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacology of adrenergic neuronal responses in the cerebral cortex: evidence for excitatory alpha- and inhibitory beta-receptors.
    Bevan P; Bradshaw CM; Szabadi E
    Br J Pharmacol; 1977 Apr; 59(4):635-41. PubMed ID: 15697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine.
    Kimber JR; Watson L; Mathias CJ
    Lancet; 1997 Jun; 349(9069):1877-81. PubMed ID: 9217760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenergic receptors in Parkinson's disease.
    Cash R; Ruberg M; Raisman R; Agid Y
    Brain Res; 1984 Nov; 322(2):269-75. PubMed ID: 6095967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of Parkinson's disease with multiple drugs].
    Kuno S
    Nihon Rinsho; 1997 Jan; 55(1):59-64. PubMed ID: 9014424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
    Ceiślak M; Komoszyński M
    Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From beta-blockers to Parkinson's disease in respect of essential tremor.
    Vogelnik K; Kojovic M
    Mov Disord; 2019 Jan; 34(1):153. PubMed ID: 30653724
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to: From beta-blockers to Parkinson's disease in respect of essential tremor.
    Gronich N; Auriel E; Lavi I; Rennert G; Saliba W
    Mov Disord; 2019 Jan; 34(1):154. PubMed ID: 30653730
    [No Abstract]   [Full Text] [Related]  

  • 10. The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.
    Haapalinna A; Leino T; Heinonen E
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):342-51. PubMed ID: 14566451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.
    Hara M; Fukui R; Hieda E; Kuroiwa M; Bateup HS; Kano T; Greengard P; Nishi A
    J Neurochem; 2010 May; 113(4):1046-59. PubMed ID: 20236221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenoceptor mechanisms in the regulation of contractile activity in the human cervix.
    Bryman I; Lindblom B; Norström A; Sahni S
    Obstet Gynecol; 1984 Sep; 64(3):363-7. PubMed ID: 6146956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pharmacological and binding assays for ten beta-adrenoceptor blocking agents and two beta-adrenoceptor agonists.
    Bieth N; Rouot B; Schwartz J; Velly J
    Br J Pharmacol; 1980 Mar; 68(3):563-9. PubMed ID: 6132636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
    Baker JG
    Br J Pharmacol; 2005 Feb; 144(3):317-22. PubMed ID: 15655528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic cardiac neurons involved in cardiac regulation possess alpha 1-, alpha 2-, beta 1- and beta 2-adrenoceptors.
    Armour JA
    Can J Cardiol; 1997 Mar; 13(3):277-84. PubMed ID: 9117916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alpha-2 adrenergic receptors and Parkinson's disease].
    Bonnet AM
    Presse Med; 2002 Jul; 31(25):1193-5. PubMed ID: 12192732
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of the receptor mediating the antianaphylactic effects of beta-adrenoceptor agonists in human lung tissue in vitro.
    Butchers PR; Skidmore IF; Vardey CJ; Wheeldon A
    Br J Pharmacol; 1980; 71(2):663-7. PubMed ID: 6162501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway.
    Chopin P; Colpaert FC; Marien M
    J Pharmacol Exp Ther; 1999 Feb; 288(2):798-804. PubMed ID: 9918591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive responses of a human cystic artery: adrenoceptor characterization.
    Wyse DG
    Br J Clin Pharmacol; 1988 Jun; 25(6):741-9. PubMed ID: 2904823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of alpha 1-adrenoceptors in rat renal cortex: comparison of [3H]-prazosin binding with the alpha 1-adrenoceptor modulating gluconeogenesis under physiological conditions.
    McPherson GA; Summers RJ
    Br J Pharmacol; 1982 Sep; 77(1):177-84. PubMed ID: 6127133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.